JB Chemicals Releases Audited Standalone and Consolidated Financial Results for FY 2026
J. B. Chemicals & Pharmaceuticals Limited announced its audited and reviewed financial results for the fiscal year ended March 31, 2026. The comprehensive report includes both standalone and consolidated financial statements, providing an overview of the company's performance and financial position for the year and the quarter ended March 31, 2026.The company confirmed that the statutory auditors, Deloitte Haskins & Sells LLP, have issued an unmodified opinion on the audited standalone and consolidated financial results for the year ended March 31, 2026.
Financial Highlights (In Lakhs)
The consolidated financial results for the year ended March 31, 2026, show a significant increase in revenue and comprehensive income compared to the previous year.The consolidated statement of assets and liabilities showed the following totals:
| Metric | As at 31-03-2026 | As at 31-03-2025 |
|---|---|---|
| Total Assets | 496,865 | 427,378 |
| Total Equity | 415,922 | 343,332 |
| Total Liabilities | 80,943 | 84,046 |
| Total Equity and Liabilities | 496,865 | 427,378 |
Consolidated Income Overview
The consolidated financial results detailed strong performance across key income and expense metrics:| Financial Metric | Year Ended 31-03-2026 (Audited) | Year Ended 31-03-2025 (Audited) |
|---|---|---|
| Total Income (Revenue + Other Income) | 3,95,631 | 3,75,766 |
| Total Expenses | 3,22,843 | 3,06,892 |
| Net Profit After Tax | 70,947 | 65,958 |
| Total Comprehensive Income | 73,623 | 66,812 |
The company's Standalone financial results for the year ended March 31, 2026, showed a total income of 3,94,517 lakhs, resulting in a net profit after tax of 67,410 lakhs.
Cash Flow and Financial Activities
Cash Flow Summary (In Lakhs):| Activity | Year Ended 31-03-2026 | Year Ended 31-03-2025 |
|---|---|---|
| Net Cash from Operating Activities | 70,393 | 90,245 |
| Net Cash Used in Investing Activities | (58,588) | (29,589) |
| Net Cash Used in Financing Activities | (12,311) | (57,968) |
| Cash and Cash Equivalents at Year End | 11,018 | 11,509 |
The company reported a total cash generated from operations of 96,018 lakhs for the fiscal year 2026.
Dividend Declaration and Related Party Transactions
The Board of Directors, at its meeting held on May 11, 2026, recommended a final dividend of ₹ 9.30 per equity share of ₹ 1 each for the year 2025-26.Regarding related party transactions for the half year ended March 31, 2026, the group recorded transactions with subsidiaries including OOOUnique Pharmaceutical Laboratories, Unique Pharmaceutical Laboratories FZE, and JBCPL Philippines Inc. These transactions encompassed activities such as the sale of goods, marketing service fees, and compensation costs associated with ESOPs.
Auditor's Conclusion
The report emphasizes that the company maintains a commitment to transparent financial reporting, with its results prepared in compliance with Indian Accounting Standards (Ind AS). The auditors confirmed that the annual financial results for both the standalone and consolidated entities provide a true and fair view, leading to an unmodified opinion on the accounts.JBCHEPHARM Stock Price Movement
Today, JB Chemicals & Pharmaceuticals Limited shares edged higher, closing at ₹2209.2, marking a strong 2.93% gain. The stock rallied on a volume of 584,031 shares and approached its 52-week high of ₹2224.9 during the trading session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.